{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-023810","form_type":"8-K","ticker":"ENSC","cik":"0001716947","company_name":"Ensysce Biosciences, Inc.","filed_at":"2026-05-15T20:20:37+00:00","discovered_at":"2026-05-15T20:28:00.266335+00:00","generated_at":"2026-05-15T21:11:32.233827+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ensysce Q1 net loss $3.6M; cash $0.7M; Phase 3 trial 50% enrolled; strategic review underway","bullets":["Net loss attributable to common stockholders $3.6M vs $1.9M in Q1 2025; R&D expense rose to $3.3M on Phase 3 costs.","Cash and equivalents $0.7M at March 31, 2026; subsequent $2.0M convertible preferred financing closed April 7.","Achieved 50% of interim enrollment target in pivotal PF614-301 Phase 3 trial for moderate to severe pain.","IRB approval secured for Part 3 of PF614-MPAR-102; first peer-reviewed MPAR data published in Journal of Opioid Management.","Board initiated formal review of strategic alternatives, including partnerships and licensing opportunities."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-023810","json":"https://secwatch.observer/filing/0001493152-26-023810.json","markdown":"https://secwatch.observer/filing/0001493152-26-023810.md","text":"https://secwatch.observer/filing/0001493152-26-023810.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716947/000149315226023810/0001493152-26-023810-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716947/000149315226023810/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T21:11:32.233827+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f41eb8c2e829b6aaf2d0f88ab93377ed7d5ef43f","claim":"Ensysce Biosciences, Inc. reported financial results for first quarter ended March 31, 2026.","evidence_excerpt":"On May 15, 2026, Ensysce Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315226023810/0001493152-26-023810-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}